MARKET

CRDF

CRDF

Cardiff Oncology Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.220
-0.180
-5.29%
Opening 15:45 06/05 EDT
OPEN
3.360
PREV CLOSE
3.400
HIGH
3.383
LOW
3.060
VOLUME
391.86K
TURNOVER
--
52 WEEK HIGH
3.920
52 WEEK LOW
0.7010
MARKET CAP
39.62M
P/E (TTM)
-1.5207
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CRDF stock price target is 14.50 with a high estimate of 23.00 and a low estimate of 6.00.

EPS

CRDF News

More
50 Stocks Moving In Tuesday's Mid-Day Session
Gainers Tenax Therapeutics Inc (NASDAQ: TENX) shares climbed 42.3% to $2.07 after the company reported results from its Phase 2 trial of Levosimendan. The trial demonstrated a significant reduction in right atrial and pulmonary capillary wedge pressures.
Benzinga · 3d ago
Stocks That Hit 52-Week Highs On Tuesday
On Tuesday, 95 companies set new 52-week highs.
Benzinga · 3d ago
71 Biggest Movers From Yesterday
Gainers Cemtrex, Inc. (NASDAQ: CETX) shares climbed 172.4% to close at $2.58 on Monday following earlier press release highlighting release of new thermal body temperature measurement camera, the V1100B-THM-TEMP.
Benzinga · 3d ago
Cardiff Oncology Data Continues to Demonstrate Efficacy of Onvansertib in Patients with KRAS-Mutated Metastatic Colorectal Cancer Presented at ASCO
PR Newswire · 05/29 13:30
Cardiff Reports Data Presented At ASCO For Onvansertib For KRAS-Mutated Metastatic Colorectal Cancer Shows Continued Efficacy
Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal
Benzinga · 05/29 12:43
The Daily Biotech Pulse: ASCO Presentations Begin, Altimmune Pops On Insider Buying, Immutep Gets R&D Grant
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 28)
Benzinga · 05/29 11:22
65 Biggest Movers From Yesterday
Gainers ARCA biopharma, Inc. (NASDAQ: ABIO) shares climbed 386.3% to close at $19.21 on Thursday after the company announced the development program for its AB201 treatment of coronavirus associated with coagulopathy.
Benzinga · 05/29 09:35
48 Stocks Moving In Thursday's Mid-Day Session
Gainers ARCA biopharma, Inc. (NASDAQ: ABIO) shares jumped 207.6% to $12.15 after the company announced the development program for its AB201 treatment of coronavirus associated with coagulopathy.
Benzinga · 05/28 16:28

Industry

Biotechnology & Medical Research
-0.34%
Pharmaceuticals & Medical Research
+0.20%

Hot Stocks

Symbol
Price
%Change

About CRDF

Cardiff Oncology Inc., formerly Trovagene, Inc., is a clinical-stage biotechnology company. The Company is focused on developing treatment options for cancer patients. It is developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. Its clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). Its programs include the development of onvansertib in a Phase-I b/2 study of onvansertib in combination with FOLFIRI/Avastin in mCRC; a Phase II study of onvansertib in combination with Zytiga (abiraterone)/prednisone in Zytiga-resistant mCRPC, and a Phase-II study of onvansertib in combination with decitabine in AML.
More

Webull offers kinds of Cardiff Oncology Inc stock information, including NASDAQ:CRDF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRDF stock news, and many more online research tools to help you make informed decisions.